Intersect ENT(NSDQ:XENT) said today that it won FDA approval for its Propel Contour steroid-releasing implant for the treatment of chronic sinusitis in the frontal and maxillary sinsuses.
The Menlo Park, Calif.-based company’s portfolio of steroid-releasing implants are used in patients undergoing ethmoid, frontal or maxillary surgeries to treat chronic sinusitis.
Get the full story at our sister site, Drug Delivery Business News.
The post Intersect ENT wins FDA nod for Propel Contour steroid-releasing implant appeared first on MassDevice.
